Connection
Michael Berquist Ii to Dopamine
This is a "connection" page, showing publications Michael Berquist Ii has written about Dopamine.
|
|
Connection Strength |
|
 |
|
 |
|
0.740 |
|
|
|
-
Fantegrossi WE, Wilson CD, Berquist MD. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metab Rev. 2018 Feb; 50(1):65-73.
Score: 0.564
-
Berquist MD, Baker LE. Characterization of the discriminative stimulus effects of 3,4-methylenedioxypyrovalerone in male Sprague-Dawley rats. Behav Pharmacol. 2017 08; 28(5):394-400.
Score: 0.136
-
Hyatt WS, Berquist MD, Chitre NM, Russell LN, Rice KC, Murnane KS, Fantegrossi WE. Repeated administration of synthetic cathinone 3,4-methylenedioxypyrovalerone persistently increases impulsive choice in rats. Behav Pharmacol. 2019 10; 30(7):555-565.
Score: 0.040